Skip to content

Study · Non-randomized trial · 1996

4 results

[Thymogen in the treatment of type-1 diabetes mellitus].

Zhuk EA, Galenok VA

Terapevticheskii arkhiv1 Jan 1996

PMID9026934 (opens in a new tab)PepBankPUB-09026934
Publisher pageAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In patients with type 1 diabetes and secondary immunodeficiency, thymogen removed signs of secondary immunodeficiency.

    In plain wordsIn patients with type 1 diabetes and secondary immunodeficiency, thymogen removed signs of immune deficiency.

    Peptide
    Thymogen (oglufanide)
    Outcome
    DecreaseSecondary immunodeficiency signs
    Study

    n: not reported in source

    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    It was found that thymogen removes signs of secondary immunodeficiency due to activation of T-lymphocyte differentiation.
    1 context sentence
    Summary · context
    Thymogen effect was assessed in patients with type 1 diabetes mellitus with clinical and laboratory evidence of secondary immunodeficiency.
  2. 02HumanNon-randomized trialMechanism

    In patients with type 1 diabetes and secondary immunodeficiency, thymogen activated T-lymphocyte differentiation.

    In plain wordsIn patients with type 1 diabetes and secondary immunodeficiency, thymogen activated immune cell differentiation.

    Peptide
    Thymogen (oglufanide)
    Outcome
    IncreaseT-lymphocyte differentiation
    Study

    n: not reported in source

    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    It was found that thymogen removes signs of secondary immunodeficiency due to activation of T-lymphocyte differentiation.
    1 context sentence
    Summary · context
    Thymogen effect was assessed in patients with type 1 diabetes mellitus with clinical and laboratory evidence of secondary immunodeficiency.
  3. 03HumanNon-randomized trialEfficacy outcome

    In patients with type 1 diabetes and secondary immunodeficiency, a clinical effect of thymogen occurred in 94.4%.

    In plain wordsIn patients with type 1 diabetes and secondary immunodeficiency, 94.4% showed a clinical effect with thymogen.

    Peptide
    Thymogen (oglufanide)
    Outcome
    Direction not reportedClinical response
    Study

    n: not reported in source

    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Measurements

    Clinical effect
    94.4%
    patients receiving thymogen

    Source sentences

    Summary
    Clinical effect of thymogen was registered in 94.4%, laboratory effect in 83.3% of patients.
    1 context sentence
    Summary · context
    Thymogen effect was assessed in patients with type 1 diabetes mellitus with clinical and laboratory evidence of secondary immunodeficiency.
  4. 04HumanNon-randomized trialEfficacy outcome

    In patients with type 1 diabetes and secondary immunodeficiency, a laboratory effect of thymogen occurred in 83.3%.

    In plain wordsIn patients with type 1 diabetes and secondary immunodeficiency, 83.3% showed a laboratory effect with thymogen.

    Peptide
    Thymogen (oglufanide)
    Outcome
    Direction not reportedLaboratory response
    Study

    n: not reported in source

    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Measurements

    Laboratory effect
    83.3%
    patients receiving thymogen

    Source sentences

    Summary
    Clinical effect of thymogen was registered in 94.4%, laboratory effect in 83.3% of patients.
    1 context sentence
    Summary · context
    Thymogen effect was assessed in patients with type 1 diabetes mellitus with clinical and laboratory evidence of secondary immunodeficiency.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.